Life Science Investing "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List 08 December
Life Science Investing Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting 05 December
Life Science Investing Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025 03 December
